{
    "clinical_study": {
        "@rank": "85934", 
        "brief_summary": {
            "textblock": "Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly\n      S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or\n      IV platinum resistant ovarian cancer or primary peritoneal carcinoma."
        }, 
        "brief_title": "Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer", 
        "completion_date": {
            "#text": "September 2007", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The goals of this study are to determine the objective response rate, to determine time to\n      disease progression, duration of response, and survival, and to identify the maximum\n      tolerated weekly dose and principal toxicities of S-8184 in this patient population."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Histologic diagnosis of ovarian cancer or primary peritoneal carcinoma\n\n        Stage III or IV disease\n\n        One and only one prior cytotoxic chemotherapy regimen which must have included a platinum\n        agent\n\n        Platinum resistant disease, defined as documented progression within six months of\n        completion of first line therapy\n\n        Adult (18 years of age or older) patients\n\n        Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than\n        100,000/mm3)\n\n        Serum creatinine less than 2.0 mg/dL\n\n        Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of\n        institutional normal values\n\n        ECOG performance status of 0 - 2\n\n        Bidimensional measurable or clinically evaluable disease\n\n        Patients who have signed an IRB / Ethics Committee approved informed consent\n\n        Life expectancy at least 12 weeks\n\n        Patient has fully recovered from any previous surgery (at least 4 weeks since major\n        surgery)\n\n        Patient has a negative pregnancy test prior to study entry if premenopausal.  (Patients of\n        child bearing potential must use a medically effective form of contraception during the\n        treatment.)\n\n        Exclusion Criteria:\n\n        Patients who have received any taxane-containing preparation including Taxol (paclitaxel)\n        or Taxotere (docetaxel)\n\n        Females who are pregnant or lactating\n\n        Patients with peripheral neuropathy NCI-CTC grade 2 or greater\n\n        Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal\n        therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of\n        study entry\n\n        Patients who have had an investigational agent within 4 weeks of study entry\n\n        Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00034151", 
            "org_study_id": "SON-8184-1061"
        }, 
        "intervention": {
            "intervention_name": "S-8184 Paclitaxel Injectable Emulsion", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2009", 
        "number_of_arms": "1", 
        "official_title": "A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Determine the objective and partial response rates", 
            "safety_issue": "No", 
            "time_frame": "No time frame-based on number of patients"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034151"
        }, 
        "responsible_party": {
            "name_title": "Monica Krieger, VP Regulatory Affairs", 
            "organization": "OncoGenex Pharmaceuticals"
        }, 
        "secondary_outcome": {
            "measure": "Time to progression, duration of response and duration of survival", 
            "safety_issue": "No", 
            "time_frame": "Based on number of patients"
        }, 
        "source": "OncoGenex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OncoGenex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2009"
    }, 
    "geocoordinates": {}
}